Articles with "study bempegaldesleukin" as a keyword



Photo by nci from unsplash

PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.6_suppl.tps589

Abstract: TPS589Background: Checkpoint inhibitors can achieve durable responses in cis-ineligible 1L mUC. However, use is restricted to patients whose tumors are PD-L1 high. Approximately 70% of cis-ineligib... read more here.

Keywords: pivot phase; bempegaldesleukin nktr; muc; cis ineligible ... See more keywords